SILO - Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More | Benzinga
Biden To Decide On Psychedelic Therapy Bill
President Joe Biden received the final version of a large-scale defense bill providing funding for psychedelics clinical trials for military service members.
The section calls on the Department of Defense (DOD) to establish a process for active duty service members with PTSD or traumatic brain injury (TBI) to take part in clinical trials with psilocybin, MDMA, ibogaine or 5-MeO-DMT. Read more here.
Could MDMA Revolutionize PTSD Treatment?
In a historic move, the Food and Drug Administration (FDA) is considering a new drug application (NDA) for MDMA (midomafetamine) capsules paired with psychological intervention for the potential treatment of PTSD.
If approved, it would become the first federally legal psychedelic-assisted therapy.
The filing marks the first New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA paired with psychological intervention for the potential treatment of PTSD. Keep reading here.
DEA Suggests Placing 2 Psychedelics In Strictest Drug Category
On Dec. 12, the Drug Enforcement Administration (DEA) and the Justice Department jointly released a proposed rule to place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I under the federal Controlled Substances Act (CSA).
Both DOI and DOC are hallucinogens that were first synthesized by famed psychedelics researcher Alexander Shulgin. They are presumed to hold subjective effects similar to LSD. However, their effects may last longer and provide a more energetic feeling. Read more HERE.
Meanwhile, the fate of Dr. Sunnil Aggarwal’s long-standing battle for the federal rescheduling of psilocybin for end-of-life cancer patients just hit another obstacle.
An appellate panel of the U.S. Ninth Circuit Court of Appeals rejected a request for rehearing the court’s former ruling, which ...